PBYI PE Ratio & Valuation, Is PBYI Overvalued

Historical Valuation

Puma Biotechnology Inc (PBYI) is now in the Overvalued zone, suggesting that its current forward PS ratio of 1.26 is considered Overvalued compared with the five-year average of -76.36. The fair price of Puma Biotechnology Inc (PBYI) is between 3.50 to 5.84 according to relative valuation method. Compared to the current price of 5.88 USD , Puma Biotechnology Inc By Overvalued By 0.84%.

Relative Value

Fair Zone

3.50-5.84

Current Price：5.88

0.84%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Puma Biotechnology Inc (PBYI) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Puma Biotechnology Inc (PBYI) has a current Price-to-Book (P/B) ratio of 2.52. Compared to its 3-year average P/B ratio of 3.42, the current P/B ratio is approximately -26.25% higher. Relative to its 5-year average P/B ratio of 1.85, the current P/B ratio is about 36.28% higher. Puma Biotechnology Inc (PBYI) has a Forward Free Cash Flow (FCF) yield of approximately 14.74%. Compared to its 3-year average FCF yield of 16.29%, the current FCF yield is approximately -9.47% lower. Relative to its 5-year average FCF yield of 7.63%, the current FCF yield is about 93.15% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for PBYI competitors is 1.45, providing a benchmark for relative valuation. Puma Biotechnology Inc Corp (PBYI.O) exhibits a P/S ratio of 1.26, which is -13.11% above the industry average. Given its robust revenue growth of 27.72%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of PBYI increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of PBYI in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is PBYI currently overvalued or undervalued?

What is Puma Biotechnology Inc (PBYI) fair value?

PBYI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Puma Biotechnology Inc (PBYI) is between 3.50 to 5.84 according to relative valuation method.

How does PBYI's valuation metrics compare to the industry average?

The average P/S ratio for PBYI's competitors is 1.45, providing a benchmark for relative valuation. Puma Biotechnology Inc Corp (PBYI) exhibits a P/S ratio of 1.26, which is -13.11% above the industry average. Given its robust revenue growth of 27.72%, this premium appears sustainable.

What is the current P/B ratio for Puma Biotechnology Inc (PBYI) as of Mar 12 2026?

As of Mar 12 2026, Puma Biotechnology Inc (PBYI) has a P/B ratio of 2.52. This indicates that the market values PBYI at 2.52 times its book value.

What is the current FCF Yield for Puma Biotechnology Inc (PBYI) as of Mar 12 2026?

As of Mar 12 2026, Puma Biotechnology Inc (PBYI) has a FCF Yield of 14.74%. This means that for every dollar of Puma Biotechnology Inc's market capitalization, the company generates 14.74 cents in free cash flow.

What is the current Forward P/E ratio for Puma Biotechnology Inc (PBYI) as of Mar 12 2026?

As of Mar 12 2026, Puma Biotechnology Inc (PBYI) has a Forward P/E ratio of 12.17. This means the market is willing to pay $12.17 for every dollar of Puma Biotechnology Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Puma Biotechnology Inc (PBYI) as of Mar 12 2026?

As of Mar 12 2026, Puma Biotechnology Inc (PBYI) has a Forward P/S ratio of 1.26. This means the market is valuing PBYI at $1.26 for every dollar of expected revenue over the next 12 months.

PBYI Valuation